Progyny (PGNY)
(Real Time Quote from BATS)
$26.56 USD
-0.54 (-1.99%)
Updated Aug 2, 2024 12:38 PM ET
4-Sell of 5 4
C Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
Progyny, Inc. [PGNY]
Reports for Purchase
Showing records 61 - 80 ( 104 total )
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
2023 Life Sciences & MedTech Investor Forum: Key Takeaways
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Progyny, Inc.
Industry: Medical Services
PGNY Member Portal App Showing Sharp Sequential Monthly Increases Since Its Launch in Early December
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Progyny, Inc.
Industry: Medical Services
2023 KBCM Life Sciences & MedTech Forum: Day 1 Takeaways
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
1Q Setup Bodes Well for Beat & Raise Story on Large Client Wins and Healthy Pipeline; Remain Overweight
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Another Short Report Highlighting Tech Layoffs & Balance Sheet Questions
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Healthcare IT: Recap from Large HC Industry Conference
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Progyny, Inc.
Industry: Medical Services
Expects 4Q22 and 2022 Revenue Guidance to Come in at or Near the High-End; Early Activity in 2023 with Prospective Clients Looks Very Encouraging
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department